The Queen Mary Hospital, located in Pok Fu Lam on Hong Kong Island of Hong Kong, is the public district general hospital and teaching hospital of the Faculty of Dentistry and Li Ka Shing Faculty of Medicine of the University of Hong Kong. It has 1,706 beds.

There are 1,711 beds in Queen Mary Hospital.

During the past decade, Queen Mary Hospital conducted 346 clinical trials. In the 10-year time frame, 346 clinical trials started and 93 clinical trials were completed, i.e. on average, 26.9% percent of trials that started reached the finish line to date. In the past 5 years, 172 clinical trials started and 63 clinical trials were completed. i.e. 36.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Queen Mary Hospital" #1 sponsor was "The University of Hong Kong" with 174 trials, followed by "Hospital Authority, Hong Kong" with 25 trials sponsored, "Pfizer" with 18 trials sponsored, "Boehringer Ingelheim" with 17 trials sponsored and "Hoffmann-La Roche" with 17 trials sponsored. Other sponsors include 256 different institutions and companies that sponsored additional 148 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Queen Mary Hospital" #1 collaborator was "Queen Mary Hospital, Hong Kong" with 21 trials as a collaborator, "The University of Hong Kong" with 18 trials as a collaborator, "United Christian Hospital" with 8 trials as a collaborator, "Kwong Wah Hospital" with 7 trials as a collaborator and "Pamela Youde Nethersole Eastern Hospital" with 6 trials as a collaborator. Other collaborators include 203 different institutions and companies that were collaborators in the rest 171 trials.

According to Clinical.Site data, the most researched conditions in "Queen Mary Hospital" are "Chronic Hepatitis B" (15 trials), "Hepatocellular Carcinoma" (15 trials), "Hepatitis B" (10 trials), "Stroke" (9 trials) and "Lung Cancer" (8 trials). Many other conditions were trialed in "Queen Mary Hospital" in a lesser frequency.

Most popular intervention types in "Queen Mary Hospital" are "Drug" (290 trials), "Device" (86 trials), "Other" (66 trials), "Biological" (36 trials) and "Procedure" (30 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (59 trials), "Capecitabine" (8 trials), "Cisplatin" (8 trials), "Pembrolizumab" (8 trials) and "Carboplatin" (6 trials). Other intervention names were less common.

The vast majority of trials in "Queen Mary Hospital" are 464 trials for "All" genders, 39 trials for "Female" genders and 9 trials for "Male" genders.

Currently, there are 162 active trials in "Queen Mary Hospital". 3 are not yet recruiting, 91 are recruiting, 64 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 235 completed trials in Queen Mary Hospital, 2 suspended trials, and 42 terminated clinical trials to date.

Out of the total trials that were conducted in Queen Mary Hospital, 44 "Phase 1" clinical trials were conducted, 114 "Phase 2" clinical trials and 127 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 34 trials, and there were also 146 trials that are defined as “Not Applicable".

Queen Mary Hospital has several departments that took part in Clinical trials: "Department of Anaesthesia and Intensive Care, New Territories West Cluster, Hospital Authority" - 2 trials